Lannett Cuts Deal With Celgene In Thalomid Antitrust Case

Law360, San Diego (December 07, 2011, 2:47 PM ET) -- Lannett Co. Inc. on Tuesday resolved its antitrust suit in Pennsylvania federal court alleging Celgene Corp. unfairly blocked it from launching a generic version of Celgene’s thalidomide-based cancer drug Thalomid.

U.S. Magistrate Judge L. Felipe Restrepo dismissed the action with prejudice after the parties notified the court that they had settled their claims against each other.

Samuel Israel, a Fox Rothschild LLP attorney representing Lannett, said his client was pleased with the settlement, but declined further comment because the terms of the deal were confidential....
To view the full article, take a free trial now.
Try Law360 for free for seven days
Already a subscriber? Click here to login

Already have access?

  1. Forgot your password?
  2. Sign In

Get instant access to the one-stop news source for business lawyers